Invitrogen’s DynaChip antibody analysis system is said to provide fully integrated instrumentation, reagents and software for automated detection and identification of human leukocyte antigen antibodies.
Kip Miller, senior vice president of biodiscovery at Invitrogen, said: “We’re very pleased to have received this FDA approval, which validates the accuracy of DynaChip data and demonstrates Invitrogen’s commitment to providing clinicians with accurate and more efficient solutions.”